Sprint Bioscience
1,43 SEK 0%1 investor følger denne virksomhed
Sprint Bioscience is a research company. The company develops pharmaceutical candidates that alone or in combination with other pharmaceuticals can fight cancer. The company has a project portfolio focused on attacking parts of cancer cell processes. The company's business model is based on developing projects parallel in the preclinical phase to subsequently enter into licensing agreements with the global pharmaceutical industry. The company was founded in 2009 and is headquartered in Huddinge.
Omsætning
50,49 mio.
EBIT %
-1,68 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
SPRINT
Daglig lav / høj pris
1,368 / 1,43
SEK
Markedsværdi
99,84 mio. SEK
Aktieomsætning
42,31 t SEK
Volumen
30 t
Finanskalender
Delårsrapport
30.10.2024
Årsrapport
12.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
First Venture Sweden | 14,2 % | 14,2 % |
Nordnet Pensionsförsäkring | 10,9 % | 10,9 % |
Jan Ivar Nordqvist | 10,0 % | 10,0 % |
Mats Westinius inkl WTS Invest | 8,5 % | 8,5 % |
Avanza Pension | 7,0 % | 7,0 % |
Staffan Halldin | 2,6 % | 2,6 % |
Nordea Liv & Pension | 2,5 % | 2,5 % |
Håkan Roos | 1,6 % | 1,6 % |
Björn Sjöstrand | 1,3 % | 1,3 % |
Pär Nordlund | 0,9 % | 0,9 % |
ViserAlle indholdstyper
Redeye: Sprint Bioscience Update - Robust sales and project activity
Redeye: Sprint Bioscience - Improved sales and activity
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools